SCHEMBL2946986

SCHEMBL2946986

N#Cc1nccc2oc(C(=O)Nc3ccc(Cl)cn3)c(NC(=O)C3CCC(N4CCCC4)CC3)c12

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ F10 P00742 5/20 0.41
▸ LMNA P02545 3/20 0.39
▸ TSHR P16473 2/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ DEGS1 O15121 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ GSK3B P49841 2/20 0.36
▸ GSK3A P49840 1/20 0.36
▸ GAA P10253 2/20 0.36
▸ USP30 Q70CQ3 1/20 0.35
▸ DYRK1A Q13627 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ PTBP1 P26599 1/20 0.35
▸ TYK2 P29597 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2946976 1.00 F10 (0.41) F10LMNATSHRSMN1; SMN2DEGS1
SCHEMBL13290710 0.89 NPY5R (0.47) F10LMNATSHRSMN1; SMN2DEGS1
SCHEMBL2952454 0.88 SMN1; SMN2 (0.45) F10LMNATSHRSMN1; SMN2DEGS1
SCHEMBL13290883 0.88 F10 (0.42) F10LMNATSHRSMN1; SMN2DEGS1
SCHEMBL2952462 0.88 SMN1; SMN2 (0.45) F10LMNATSHRSMN1; SMN2DEGS1
SCHEMBL13290747 0.87 F10 (0.42) F10LMNATSHRSMN1; SMN2DEGS1
SCHEMBL2952732 0.86 F10 (0.39) F10LMNATSHRSMN1; SMN2DEGS1
SCHEMBL2952735 0.86 F10 (0.39) F10LMNATSHRSMN1; SMN2DEGS1
SCHEMBL13290887 0.86 F10 (0.42) F10LMNATSHRSMN1; SMN2DEGS1
SCHEMBL2944263 0.86 F10 (0.42) F10LMNATSHRSMN1; SMN2DEGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US claimed
US-20060094724-A1 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2006-05-04 — — US claimed
EP-1582521-A1 FUSED FURAN COMPOUND TANABE SEIYAKU CO., LTD. (JP) 2005-10-05 — — EP claimed
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed
US-20060094724-A1 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2006-05-04 — — US disclosed
EP-1582521-A1 FUSED FURAN COMPOUND TANABE SEIYAKU CO., LTD. (JP) 2005-10-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156803-A1 Condensed furan compounds F2, F12, F11 F10 4/4885LMNA 832/4885TSHR 3368/4885
US-20060094724-A1 Fused furan compound F2, F12, F11 F10 4/4885LMNA 1796/4885TSHR 3045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback